| | |
Normal inflammation
|
High inflammation
|
|---|
|
Outcome
|
Factor
|
Gradient
|
p value
|
Gradient
|
p value
|
|---|
|
SDMA
|
Log2ACh
|
−0.7% (−5.6%, 4.5%)
|
0.791
|
−16.3% (−26.3%, −5.0%)
|
0.006
|
|
ADMA:SDMA
|
Log2ACh
|
2.2% (−4.5%, 9.4%)
|
0.528
|
25.6% (6.1%, 48.7%)
|
0.008
|
|
SDMA
|
Log2SNP
|
0.4% (−2.4%, 3.3%)
|
0.778
|
−6.2% (−11.5%, −0.5%)
|
0.034
|
|
ADMA:SDMA
|
AIx (HR 75)
|
−0.1% (−0.5%, 0.4%)
|
0.827
|
1.6% (0.1%, 3.1%)
|
0.033
|
- Results are from the models reported in Table 2. Since the outcome variables of SDMA and ADMA:SDMA had been log-transformed prior to analysis, the resulting coefficients were anti-logged, and converted into gradients representing the percentage increase in the outcome for a one unit increase in the factor. For the log-transformed factors, this is equivalent to the change associated with a twofold increase in the untransformed factor. Bold p values are significant at p < 0.05
-
SDMA symmetric dimethylarginine, ACh acetylcholine, ADMA asymmetric dimethylarginine, SNP sodium nitroprusside, AIx augmentation index, HR heart rate
